J Korean Ophthalmol Soc.  2009 Mar;50(3):331-335. 10.3341/jkos.2009.50.3.331.

Clinical Comparability of Dysport and Botox in Essential Blepharospasm

• Shin JH
• Jeon C
• Woo KI
• Kim YD

• KMID: 2111240
• DOI: http://doi.org/10.3341/jkos.2009.50.3.331

Abstract

PURPOSE: To compare the clinical efficacy, duration of effect, and safety of Dysport and Botox for patients with essential blepharospasm using functional disability scale.
METHODS
Patients with a confirmed diagnosis of essential blepharospasm who had received Botox (Allergan, USA) from September 2006 to May 2007 were enrolled in this study. We switched from Botox to Dysport (Ipsen, UK) after the botulinum effect of previous injection had disappeared and compared the clinical efficacy of two drugs. We used a 2.5:1 Dysport:Botox conversion ratio. The clinical efficacy of the drugs treatment was evaluated using a functional disability scale. We compared the duration of the effect and the safety of the two drugs.
RESULTS
The study included 48 patients (43 women, 5 men). There was no significant difference in mean functional disability scores or in any item of the functional disability scale. There was no significant difference in duration of effect between Botox (100.2+/-37.34 days) and Dysport (99.1+/-39.7days). There was also no significant difference in frequency of adverse reaction between Botox (13%) and Dysport (10%).
CONCLUSIONS
When a dose conversion of 2.5:1 Dysport:Botox was used for essential blepharospasm patients, the two drugs displayed almost identical clinical efficacy, duration of effect, and safety.

Keyword

Botulinum neurotoxin A; Conversion ratio; Essential blepharospasm

MeSH Terms

Blepharospasm
Botulinum Toxins, Type A
Female
Humans
Botulinum Toxins, Type A

Reference

References

1. Durif F. Clinical bioequivalence of the current commercial preparations of botulinum toxins. Eur J Neurol. 1995; 2:17–8.

2. Nüssgens Z, Roggenkämper P. Comparison of two botulinumtoxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997; 235:197–9.

3. Sampaio C, Ferreira J, Simões F, et al. DYSBOT: a single- blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A–Dysport and Botox–assuming a ratio of 4:1. Mov Disord. 1997; 12:1013–8.

4. Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the Dose of Dysport and Botox in the management of cervical dystonia and blepharospasm: The REAL DOSE study. Mov Disord. 2005; 20:937–44.

5. Dressler D. Pharmacological aspects of therapeutic botulinum toxin preparations. Nervenarzt. 2006; 77:912–21.

6. Karsai S, Adrian R, Hammers S, et al. A randomized double- blind study of the effect of Botox and Dusport/Reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol. 2007; 143:1447–9.

7. Dewandre L, Voloshchenko A, Trembach IV. Pilot study to compare the efficacy and the duration of activity of Dysport vs Botox in classical esthetic indications (forehead, glabella, crow's feet). J Med Esth et Chir Dermatol. 2003; 118:101–7.

8. Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blinded, randomized study. J Am Acad Dermatol. 2006; 55:975–80.

9. Wohlfarth K, Göschel H, Frevert J, et al. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol. 1997; 355:335–40.

10. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord. 2004; 19:129–36.

11. Grivet D, Robert PY, Thuret G, et al. Assessment of blepharospasm surgery using an improved disability scale: study of 138 patients. Ophthal Plast Reconstr Surg. 2005; 21:230–4.

12. Foster KA, Bigalke H, Aoki KR. Botulinum neurotoxin from laboratory to bedside. Neurotox Res. 2006; 9:133–40.

13. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol. 2006; 13:2–10.

14. De Almeida AT, De Boulle K. Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther. 2007; 9:17–22.